Premium
PPARδ as a therapeutic target in metabolic disease
Author(s) -
Reilly Shan M.,
Lee Chih-Hao
Publication year - 2008
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2007.11.040
Subject(s) - lipotoxicity , peroxisome proliferator activated receptor , endocrinology , ppar agonist , medicine , inflammation , receptor , mediator , metabolic syndrome , glucose uptake , insulin resistance , biology , insulin , diabetes mellitus
PPARδ is the only member in the PPAR subfamily of nuclear receptors that is not a target of current drugs. Animal studies demonstrate PPARδ activation exerts many favorable effects, including reducing weight gain, increasing skeletal muscle metabolic rate and endurance, improving insulin sensitivity and cardiovascular function and suppressing atherogenic inflammation. These activities stem largely from the ability of PPARδ to control energy balance, reduce fat burden and protect against lipotoxicity caused by ectopic lipid deposition. Therefore, PPARδ represents a novel therapeutic target and the development of PPARδ gonists/modulators may be useful for treating the whole spectrum of metabolic syndrome.